Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET

Company Participants

Dan Ferry - IR, LifeSci Communications
Marcio Souza - President & CEO
Tim Kelly - CFO

Conference Call Participants

Ritu Baral - TD Cowen
Yasmeen Rahimi - Piper Sandler
Joon Lee - Truist Securities
Francois Brisebois - Oppenheimer
Yatin Suneja - Guggenheim
Douglas Tsao - H.C. Wainwright
Kambiz Yazdi - Jefferies
Ami Fadia - Needham
Joel Beatty - Baird
Laura Chico - Wedbush Securities

Operator

Good day and thank you for standing by. Welcome to the Praxis Precision Medicines Third Quarter 2024 Corporate Update. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions].

I would now like to hand the conference over to your speaker today, Dan Ferry from LifeSci.

Dan Ferry

Good morning, and welcome to Praxis Precision Medicines third quarter 2024 financial results and business update conference call. This call is being webcast live and can be accessed on the Investors section of Praxis' website at www.praxismedicines.com.

Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines, and financial projections. While these forward-looking statements represent Praxis views as of today, they should not be relied upon as representing the company's views in the future. Praxis may update these statements in the future, but is not taking on an obligation to do so. Please refer to Praxis' most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business.

Joining the call today are Marcio Souza, President and Chief Executive Officer of Praxis; and Tim Kelly, Chief Financial Officer. After providing updates on our key programs, there will be a brief question-and-answer session.

With that, it's my pleasure to turn the call over to Marcio.

Marcio Souza

Thank you. Good morning, and welcome to the Praxis third quarter 2024 conference call.

This past quarter, we remain laser-focused on advancing our pipeline as we gear up for next year to have four programs in registration totaling to a substantial multibillion dollar opportunity. The Phase 3 study in Essential Tremor Essential3 for our lead program ulixacaltamide continues to progress well. We have confirmed all aspects of the interim analysis and are now updating the plans to have the results in Q1 2025. Both studies are well-powered and controlled for success because there's a range of outcomes for each study as well as the interim analysis in the coming months. We decided that we will only share an update on timing for both Study 1 and Study 2 once we have evaluated the recommendation from the interim review board for the interim analysis.